Develops off-the-shelf precision T cell therapeutics. Focuses on addressing unmet medical needs in virology, oncology, and neurology. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 6 of the last 7 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 14 buys and 7 sells. Management buying with its own money is usually read as a good sign.
A loss of $26.3M against $0 in annual sales.
The stock sits at $0.06. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.